Venture capital deals

Opsona Therapeutics Ltd., a Dublin-based innate immune drug development company, has raised €33 million in Series C funding. BB Biotech Ventures and return backer Novartis Venture Fund co-led the round. Other new investors included Sunstone Capital, Baxter Ventures, Amgen Ventures and EMBL Ventures, while other returnees included Fountain Healthcare Partners, Roche Venture Fund and Seroba Kernel Life Sciences. www.opsona.com

RainDance Technologies Inc., a Lexington, Mass.-based developer of microdroplet-based solutions for single molecule and single cell analysis, has raised $20 million in Series E funding. Myriad Genetics Inc. (Nasdaq: MYGN) was joined by return backers Mohr Davidow Ventures, Quaker BioVentures, Alloy Ventures, Acadia Woods Partners and Sectoral Asset Management.www.raindancetech.com